Research programme: targeted EZH2 inhibitors - Epizyme/Eisai

Drug Profile

Research programme: targeted EZH2 inhibitors - Epizyme/Eisai

Alternative Names: EPZ 5687; EPZ005687; EZH2 inhibitors - Epizyme/Eisai

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Epizyme
  • Developer Eisai Co Ltd; Epizyme
  • Class Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action EZH2 enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Lymphoma; Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Lymphoma in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top